Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Assets Average: 2011-2025

Historic Assets Average for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Sep 2025 value amounting to $90.2 million.

  • Lineage Cell Therapeutics' Assets Average fell 9.51% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.2 million, marking a year-over-year decrease of 9.51%. This contributed to the annual value of $107.1 million for FY2024, which is 4.65% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Assets Average is $90.2 million, which was down 10.92% from $101.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Assets Average high stood at $159.5 million for Q1 2022, and its period low was $90.2 million during Q3 2025.
  • In the last 3 years, Lineage Cell Therapeutics' Assets Average had a median value of $104.9 million in 2024 and averaged $105.7 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Assets Average skyrocketed by 44.88% in 2021 and then declined by 25.76% in 2023.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Assets Average stood at $152.9 million in 2021, then fell by 16.66% to $127.4 million in 2022, then declined by 18.70% to $103.6 million in 2023, then rose by 1.27% to $104.9 million in 2024, then fell by 9.51% to $90.2 million in 2025.
  • Its Assets Average stands at $90.2 million for Q3 2025, versus $101.3 million for Q2 2025 and $112.5 million for Q1 2025.